- Research article
- Open Access
- Open Peer Review
Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study
© Katsumata et al; licensee BioMed Central Ltd. 2010
- Received: 11 December 2009
- Accepted: 23 January 2010
- Published: 23 January 2010
Previous studies of magnetic resonance imaging (MRI) as a diagnostic tool for central nervous system (CNS) syndromes in systemic lupus erythematosus (SLE) contained several limitations such as study design, number of enrolled patients, and definition of CNS syndromes. We overcame these problems and statistically evaluated the diagnostic values of abnormal MRI signals and their chronological changes in CNS syndromes of SLE.
We prospectively studied 191 patients with SLE, comparing those with (n = 57) and without (n = 134) CNS syndrome. CNS syndromes were characterized using the American College of Rheumatology case definitions.
Any abnormal MRI signals were more frequently observed in subjects in the CNS group (n = 25) than in the non-CNS group (n = 32) [relative risk (RR), 1.7; 95% confidence interval (CI), 1.1-2.7; p = 0.016] and the positive and negative predictive values for the diagnosis of CNS syndrome were 42% and 76%, respectively. Large abnormal MRI signals (ø ≥ 10 mm) were seen only in the CNS group (n = 7; RR, 3.7; CI, 2.9-4.7; p = 0.0002), whereas small abnormal MRI signals (ø < 10 mm) were seen in both groups with no statistical difference. Large signals always paralleled clinical outcome (p = 0.029), whereas small signals did not (p = 1.000).
Abnormal MRI signals, which showed statistical associations with CNS syndrome, had insufficient diagnostic values. A large MRI signal was, however, useful as a diagnostic and surrogate marker for CNS syndrome of SLE, although it was less common.
- Systemic Lupus Erythematosus
- Systemic Lupus Erythematosus Patient
- Conventional Magnetic Resonance Imaging
- Magnetic Resonance Imaging Signal
- Active Central Nervous System
Central nervous system (CNS) lupus is a serious and potentially life-threatening manifestation of systemic lupus erythematosus (SLE), occurring in 37-95% of cases, and is associated with an increased risk of death . Despite its frequency and severity, the lack of a diagnostic gold standard makes it challenging to differentiate primary CNS lupus from secondary neuropsychiatric (NP) manifestations unrelated to SLE at their onsets [1–3]. The American College of Rheumatology (ACR) has developed a standardized nomenclature system that provides case definitions for 19 NP syndromes associated with SLE, including reporting standards and recommendations for laboratory and imaging tests . Although this standardized nomenclature has helped to clarify a complicated situation, its usefulness as a clinical diagnostic criterion remains to be determined.
While neurological or psychological examinations are still the cornerstones for the diagnosis of CNS lupus, neuroimaging, electroencephalography and cerebrospinal fluid tests are also used [1, 2, 4–8]. Among conventional and more recent neuroimaging tools, conventional magnetic resonance imaging (MRI) still remains the modality of choice because of its availability and accessibility. Newer tools, such as magnetic resonance spectroscopy (MRS), magnetization transfer imaging (MTI), diffusion weighted imaging (DWI), perfusion weighted imaging (PWI), single photon emission computed tomography (SPECT), and positron emission tomography (PET) are still investigational (SPECT has probably been most established among these), although they have provided data to greatly improve our understanding of CNS lupus [4–7]. However, even the diagnostic validity and usefulness of conventional MRI is not yet fully established, because most published studies are small in size (n < 100, mostly < 50), retrospective, or based on non-standardized case definitions and some include only NPSLE, not SLE patients without CNS syndromes [2, 4–7, 9]. In order to overcome these problems of the previous studies we prospectively enrolled the largest number of SLE patients with or without active CNS syndrome which was categorized based on the ACR standardized case definitions and evaluated the accuracy and usefulness of conventional MRI in the diagnosis of CNS syndrome. We also assessed the suitability of conventional MRI as a surrogate marker for CNS lupus.
This was a prospective study of 191 SLE patients with or without NP syndromes who were admitted to the Aoyama Hospital of The Tokyo Women's Medical University from August 1994 through October 2003. All these patients had 4 or more revised ACR (formerly, the American Rheumatism Association) criteria for SLE . At our institution, those patients suspected of or newly diagnosed as having SLE were typically admitted for systemic evaluation regardless of the severity of the disease, and were eligible for inclusion in the study. Previously diagnosed SLE patients whose disease (NP syndrome or other manifestations of SLE) flared were also enrolled in the study. A total of 269 patients with SLE gave informed consent for inclusion in this study, including their MRI examinations during the above period. Among these 269 patients, those who had non-SLE-related NP manifestations arising from infection, uremia, electrolyte imbalance, hypoxia, brain tumor, trauma, primary mental disease or drug use (n = 45) or past histories of NP involvement (n = 33) were excluded prior to MRI scans. The patients were excluded because we wanted to compare recently (i.e. within a month) diagnosed active CNS lupus patients to non-NPSLE patients and because the unrelated conditions could affect current symptoms or laboratory and MRI findings. At the time of admission to the hospital, each patient completed a standardized medical history, including medication use, and had physical examinations that included neurologic and rheumatologic examinations. Psychiatric examinations were employed when indicated. Serology profiling for each patient was performed using standard immunoassays. The activity of SLE was measured using the SLE Activity Index (SLEDAI) . Treatment with corticosteroids or immunosuppressive drugs was instituted as indicated following completion of these evaluations. One non-NPSLE patient at admission, who later developed NPSLE, was reevaluated at the onset of the NP syndrome (a mood disorder in this patient) and was reclassified into the CNS group. In this patient, data from the reevaluation, including the results of MRI, were used. Subjects were classified into the CNS group or the non-CNS group according to the presence or absence of active CNS syndromes. The CNS group was then further classified into the neurologic disorders group consisting of patients with neurologic disorders with or without other NP syndromes, or the psychiatric disorders group comprising patients with psychiatric disorders with or without other NP syndromes [2, 4, 8, 12]. Thirteen patients were classified into both neurologic and psychiatric disorders groups. Detailed diagnostic criteria for these groups are described below. The study was approved by the Ethical Committee of our institution and the Helsinki declaration was followed throughout the study.
Diagnosis of CNS lupus
Although ACR nomenclature and case definitions include 12 CNS syndromes and 7 peripheral nervous system syndromes [2, 4, 8, 12], we included only the 12 CNS syndromes in the present study because of the substantial differences in anatomy, function, and clinical characteristics between the central and peripheral nervous systems. Slight or mild cognitive dysfunction without significant clinical impairment, as revealed by the detailed neuropsychological tests described below in "Evaluation of psychological impairment," was excluded from the CNS syndromes in our study. Using published normative data, patients in this category (n = 3) exhibited less than the median of normal controls by 2 standard deviation (SD) in 2 or more of areas of cognitive function without significant clinical impairment . Tension headache, or episodic tension type headache, was also excluded from our study.
The final clinical diagnosis and classification of the various NP syndromes for inclusion in the study were made by an experienced rheumatologist (M. Hara) and psychiatrist (K. N.), according to the standardized ACR nomenclature and case definitions for neuropsychiatric lupus syndromes . These decisions were based on the medical history and neuropsychological examinations by rheumatologists, an experienced neurologist (S. U.) and a psychiatrist (K. N.) and supported by conventional laboratory tests and appropriate complementary tests, including MRI, electroencephalography, and cerebral spinal fluid tests, and the clinical course. Cases before the ACR nomenclature and case definitions for NPSLE were published in 1999 were originally diagnosed and classified according to another criteria and later re-diagnosed retrospectively according to the ACR criteria.
Clinical improvement of CNS lupus was defined as either sustained complete recovery or recovery with minor residual deficits that no longer required hospitalization. Stabilization was defined as the status in which no new clinical (i.e., neurologic or psychiatric) abnormalities occurred, although the previous abnormalities remained. Deterioration was defined as the status in which previous neuropsychiatric symptoms were exacerbated or new ones developed during follow-up [14, 15].
Evaluation of psychological impairment
Cognitive function was evaluated using the Mini Mental Status Examination  and the ACR-suggested test battery , including the WAIS-R/Digit Span (Forward) , Trail Making Test (Part B) , WAIS-R/Digit Span (Backward) , Wisconsin Card Sorting Test , Rey Auditory-Verbal Learning Test , WAIS-R/Block Design , Animal Naming Test , WAIS-R/Similarities , Trail Making Test (Part A) , and WAIS-R/Digit Symbol Substitution Test . Mood and behavioral dysfunction was assessed by clinical observation, patient history and standardized instruments, such as the Profile of Mood States . However, these formal neuropsychological tests were not performed routinely in all patients and the diagnosis of cognitive, mood, or behavioral dysfunction was on the basis of clinical assessment using the ACR definitions , rather than formal neuropsychological testing, especially in cases where disturbance of consciousness, such as acute confusional state, created difficulty in taking the tests. The impact of disturbance on daily life and prior occupational and social functioning was determined from information provided by the patient or other informants.
Magnetic resonance imaging (MRI)
MRI was performed using a 1.5T MR scanner (Toshiba Medical Systems, Otawara, Tochigi, Japan) within a week from admission and within a month from onset of NP symptoms in the CNS group. Scans were aligned parallel to the axial plane through the anterior to posterior commissure and covered the entire brain in all sequences. T1-weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) images were acquired from all patients who had brain MRIs. The software, but not the hardware of the MR scanner was updated once in 2000, which improved its resolution but did not practically influence the sensitivity of this study. The MRIs were interpreted at the time of scanning by an experienced radiologist (T. Y.) who was not blinded to all the clinical and sequential information. MRI tests were defined as 'positive' when any abnormal intensity lesion was found. The abnormal MRI signals were classified into large abnormal MRI signals (ø ≥ 10 mm) or small abnormal MRI signals (ø < 10 mm) . Mild brain atrophy, characterized by loss of brain volume, was not included among MRI abnormalities in the present study because it is not a well-established abnormality , even though it is the most frequent abnormal findings in SLE . Moderate to severe brain atrophy was not seen at the time of enrolment in the study population. CNS lupus patients who had had abnormalities in initial MRIs were reevaluated by MRI at approximately 1 year or when clinical amelioration or deterioration was determined. MRI improvement was defined as a more than 50% decrease in the number or size of abnormal MRI signals. MRI stabilization was defined as occurring when no new abnormalities were detected, but previously detected abnormalities were unchanged or only slightly changed. Deterioration was defined as when the previously detected abnormalities became exacerbated or new ones developed during follow-up .
Diagnostic tests evaluated in the present study were correlated with the final clinical diagnosis for each. Two-group comparisons were analyzed using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables. Values of p < 0.05 were considered statistically significant. Accuracy, positive predictive value (PPV), and negative predictive value (NPV) of MRI and the relative risk of CNS lupus to MRI were also calculated. All statistical analyses were performed using SPSS statistical software (version 14.0J; SPSS Inc., Tokyo, Japan).
Clinical characteristics of the patients
Characteristics of the 191 patients with SLE
n = 57
n = 134
Age at evaluation (yrs)
28 : [23, 43]
34 : [25, 45]
SLE duration at evaluation (yrs)
1 : [0, 5]
1 : [0, 4]
Malar rash/discoid rash
Oral or nasal ulcers
Lymphocytopenia (< 1500/mm3)
15 : [10, 22]
9 : [5, 11]
SLEDAI without CNS score
11 : [7, 16]
9 : [5, 11]
Anti-dsDNA antibody (RIA; IU/ml)
8 : [3, 37]
20 : [5, 98]
33.2 : [21.2, 39.2]
29.8 : [20.4, 38.3]
CNS syndromes of SLE patients (n = 191)
Manifestaions of CNS lupus*
Movement disorder (chorea)
Seizures and seizure disorders
Acute confusional state
MRI as a diagnostic tool for CNS lupus in 191 patients with SLE
1.7 (1.1 - 2.7)
2.3 (1.3 - 4.1)
1.9 (1.1 - 3.4)
Large MRI signal as a diagnostic tool for CNS lupus in 191 patients with SLE
Negative or small signal
3.7 (2.9 - 4.7)
5.6 (4.0 - 7.8)
5.3 (3.9 - 7.3)
Characteristics of the CNS lupus patients with large abnormal MRI signals
Duration of SLE (yrs)
SLEDAI without CNS
SLE-related CNS syndrome
Clinical outcome of CNS lupus
Seizure disorder, Headache
Acute confusional state
Steroids + CPA
Demyelinating syndrome, Acute confusional state
Steroids + CPA
Demyelinating syndrome, Seizure disorder, Acute confusional state
Steroids + CPA
Demyelinating syndrome, Acute confusional state
Steroids + CPA
Steroids + CPA + anticoagulant
Acute confusional state
Steroids + CPA
Chronological changes in abnormal MRI signals
Large or small MRI signal as a surrogate marker for CNS lupus in 25 SLE patients
Clinical outcome of CNS syndrome
MRI signal size
Stabilize or deteriorate
Stabilize or deteriorate
Stabilize or deteriorate
First, from the largest prospective cohort of SLE patients with or without active CNS syndrome, we found that abnormal signals from conventional MRI alone did not have sufficient predictive value to be practical for diagnosis of active CNS lupus, although they were associated with active CNS lupus. Second, after assortment by size, large signals (ø ≥ 10 mm) were found to occur only in the CNS group while small signals (ø < 10 mm) occurred in both the CNS and non-CNS groups with no significant difference in frequency. Finally, we did find that large signals were always reduced or resolved completely when CNS syndromes were ameliorated by treatment but did not change when CNS syndromes did not improve. In contrast, chronological changes in small signals were not related to clinical outcome. We believe this is the first report analyzing predictive values of MRI for diagnosis of active CNS lupus using a prospective study of a large cohort of patients with and without NP syndromes.
This study demonstrated that active CNS lupus was not associated with elevated "SLEDAI scores without CNS syndrome," elevated anti-DNA antibody levels, or decreased serum CH50 levels. The latter two are widely recognized and clinically used as reliable laboratory tests for estimating disease activity in patients with SLE [20, 21]. Our data support the common view that CNS syndrome in SLE may occur independently from and in the absence of serological activity or other organ involvement .
Although we observed abnormal signal intensities in the brain MRIs of the CNS group more frequently than in those of the non-CNS group, the PPV (42%) and the NPV (76%) of MRI for detecting active CNS lupus indicate that conventional MRI alone is insufficiently specific to serve as a diagnostic tool for active CNS lupus. Active CNS lupus was diagnosed in less than half of the patients with abnormal signal intensities in brain MRI, even though normal MRI findings tended to be associated with non-CNS lupus. We also categorized patients by CNS manifestations indicating neurologic or psychiatric disorders but did not find any better results. In fact, MRI has been shown to be neither very sensitive nor specific for the diagnosis of NPSLE, estimates of sensitivity and specificity being in the 30 and 40%, respectively . We would like to point out that these figures had been only estimates without solid evidence until this study. Thus, the diagnosis of CNS syndrome in SLE remains a difficult task requiring careful clinical and laboratory assessment together with such evaluation techniques as neuroimaging, electroencephalography and cerebrospinal fluid tests [7, 12].
While exploring the usefulness of conventional MRI, we found that a large MRI signal is useful as a diagnostic and surrogate marker for CNS lupus. Large abnormal MRI signals (ø ≥ 10 mm) were seen only in the CNS group whereas small abnormal MRI signals (ø < 10 mm) were seen in both groups with no significant difference. In addition, chronological changes in large signals always corresponded with clinical outcome while those of small signals did not. This kind of reversible large abnormal MRI signals has been reported [4, 12, 15, 23, 24]. These large abnormal MRI signals may include new infarcts, discrete gray matter lesions, diffuse gray matter hyperintensities, and cerebral edema. These lesions, except for infarcts, are often transitory and resolve completely with time and treatment. The large abnormal MRI signals in the present study included several types of features, such as infarcts, diffuse gray matter hyperintensities, and widespread grey and white matter T2 high signal changes resembling those in acute disseminated encephalomyelitis, accompanied by various CNS syndromes. Although these large abnormal MRI signals were attributed to different pathomechanisms, they exhibited equal usefulness as a diagnostic and surrogate marker. Therefore, our simple criterion (i.e., MRI signals with ø ≥ 10 mm) is applicable to daily clinical practice without specialized knowledge of neuroimaging and regardless of the type of CNS syndromes encountered. We believe this test will prove very beneficial for clinical assessment of the condition.
In agreement with our present findings, small punctate focal lesions in the white matter have been reported to be the most common brain MRI finding, tending to be more frequently observed in the CNS than in the non-CNS SLE patients in most published reports [6, 7, 12, 25, 26]. These lesions appear anywhere in the brain, including the brain stem, and are accompanied by a variety of clinical presentation. These small punctuate hyperintense T2-weighted focal lesions are frequently nonspecific and interpreted as consistent with focal ischemia, demyelination, vasculitis, microinfarcts, gliosis, or other conditions. These small abnormal MRI signals frequently correlate poorly with clinical manifestations, and occur in patients without marked CNS signs and symptoms. In addition, conventional MRI is not capable of differentiating between older chronic and recent acute lesions of this type.
Neuroimaging must be evaluated in the context of the brain pathology of CNS lupus . At this time, pathologic studies have basically been limited to post mortem studies of end stage SLE patients, which has seriously limited understanding of the sequence of events in the pathogenesis and progression of the disease . Moreover, there have been few paired imaging-autopsy studies . Despite the dramatic neurologic manifestations, minimal histopathologic findings in CNS lupus are typical, with apparently normal findings or nonspecific changes in the brain predominating. This general lack of specific histopathology has complicated interpretation of results found with nearly any imaging technique. For example, the autopsy of one of the patients in the present study who died from alveolar hemorrhage 5 years after showing acute confusional state and several foci of small-sized abnormal MRI signals in the white-matter showed no remarkable findings in the brain.
One of the limitations of the present study is that its subject number was insufficient for definitive conclusions about significance of conventional MRI for diagnosis of CNS lupus, although it is appreciably larger than previous studies dealing with NPSLE and MRI [15, 24, 27]. Another potential weakness arises from the fact that the MRI scans were not evaluated by multiple radiologists blinded to the clinical condition. Fortunately, it has been shown that evaluation of these scans is generally consistent among observers, so cranial MRI may be considered to be a valid technique to assess disease progression or reversal . Because we did not include SLE patients who had CNS syndromes caused by non-SLE pathologies, the value of MRI for diagnosis of these conditions was not determined by this study. Thus, it is not clear from this study whether CNS syndromes caused by non-SLE pathologies can be differentiated by MRI, including the large MRI abnormal signals.
MRI alone does not have sufficient predictive value for the diagnosis of active CNS lupus, although abnormal MRI signals showed a significant association with CNS syndrome. Importantly, a large MRI signal is a reliable and practical diagnostic and surrogate marker for CNS syndrome in SLE. The relatively small number of subjects having large MRI signals in the study indicates the need for further studies in larger numbers of patients to validate the findings.
We thank Dr. Masashi Uesato (Tokyo Women's Medical University) for assisting in construction of the database of SLE patients and Professor Shinichiro Uchiyama (Department of Neurology, Neurological Institute, Tokyo Women's Medical University) for assisting with the neurological examinations and diagnoses.
- Hanly JG, Harrison MJ: Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol. 2005, 19 (5): 799-821. 10.1016/j.berh.2005.04.003.View ArticlePubMedGoogle Scholar
- The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42 (4): 599-608. 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.Google Scholar
- Nishimura K, Harigai M, Omori M, Sato E, Hara M: Blood-brain barrier damage as a risk factor for corticosteroid-induced psychiatric disorders in systemic lupus erythematosus. Psychoneuroendocrinology. 2008, 33 (3): 395-403. 10.1016/j.psyneuen.2007.12.007.View ArticlePubMedGoogle Scholar
- Sibbitt WL, Sibbitt RR, Brooks WM: Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999, 42 (10): 2026-2038. 10.1002/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Huizinga TW, Steens SC, van Buchem MA: Imaging modalities in central nervous system systemic lupus erythematosus. Curr Opin Rheumatol. 2001, 13 (5): 383-388. 10.1097/00002281-200109000-00007.View ArticlePubMedGoogle Scholar
- Appenzeller S, Pike GB, Clarke AE: Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol. 2008, 34 (3): 361-366. 10.1007/s12016-007-8060-z.View ArticlePubMedGoogle Scholar
- Castellino G, Govoni M, Giacuzzo S, Trotta F: Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev. 2008, 7 (4): 297-304. 10.1016/j.autrev.2007.11.022.View ArticlePubMedGoogle Scholar
- Katsumata Y, Harigai M, Kawaguchi Y, Fukasawa C, Soejima M, Takagi K, Tanaka M, Ichida H, Tochimoto A, Kanno T: Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin. J Rheumatol. 2007, 34 (10): 2010-2017.PubMedGoogle Scholar
- Petri M, Naqibuddin M, Carson KA, Wallace DJ, Weisman MH, Holliday SL, Sampedro M, Narayana S, Fox PT, Franklin C: Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol. 2008, 35 (12): 2348-2354. 10.3899/jrheum.071010.View ArticlePubMedGoogle Scholar
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25 (11): 1271-1277. 10.1002/art.1780251101.View ArticlePubMedGoogle Scholar
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35 (6): 630-640. 10.1002/art.1780350606.View ArticlePubMedGoogle Scholar
- Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P: Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology. 2004, 46 (1): 15-21. 10.1007/s00234-003-1049-2.View ArticlePubMedGoogle Scholar
- Kozora E, Thompson LL, West SG, Kotzin BL: Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996, 39 (12): 2035-2045. 10.1002/art.1780391213.View ArticlePubMedGoogle Scholar
- Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG: Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med. 1995, 98 (1): 32-41. 10.1016/S0002-9343(99)80078-3.View ArticlePubMedGoogle Scholar
- Karassa FB, Ioannidis JP, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA, Moutsopoulos HM: Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 2000, 109 (8): 628-634. 10.1016/S0002-9343(00)00603-3.View ArticlePubMedGoogle Scholar
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, American Psychiatric Association, 4Google Scholar
- Wechsler D: Wechsler Adult Intelligence Scale - Revised. 1981, New York: The Psychological CorporationGoogle Scholar
- Lezak MD: Neuropsychological assessment. 1997, New York: Oxford University Press, 3Google Scholar
- McNair DM, Lorr M, Droppleman LF: Manual for the Profile of Mood States. 1992, San Diego: Educational and Industrial Testing ServiceGoogle Scholar
- Merrill JT, Buyon JP: The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol. 2005, 19 (5): 709-726. 10.1016/j.berh.2005.05.004.View ArticlePubMedGoogle Scholar
- Mills JA: Systemic lupus erythematosus. N Engl J Med. 1994, 330 (26): 1871-1879. 10.1056/NEJM199406303302608.View ArticlePubMedGoogle Scholar
- Winfield JB, Brunner CM, Koffler D: Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum. 1978, 21 (3): 289-294. 10.1002/art.1780210301.View ArticlePubMedGoogle Scholar
- Graham JW, Jan W: MRI and the brain in systemic lupus erythematosus. Lupus. 2003, 12 (12): 891-896. 10.1191/0961203303lu498oa.View ArticlePubMedGoogle Scholar
- Sibbitt WL, Sibbitt RR, Griffey RH, Eckel C, Bankhurst AD: Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis. 1989, 48 (12): 1014-1022. 10.1136/ard.48.12.1014.View ArticlePubMedPubMed CentralGoogle Scholar
- Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, Origgi L, Vanoli M, Gambini O, Vanzulli L: Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 1999, 8 (1): 11-19. 10.1191/096120399678847344.View ArticlePubMedGoogle Scholar
- Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, Ahmed A, Cauli A, Montaldo C, Passiu G: Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000, 9 (8): 573-583. 10.1191/096120300678828695.View ArticlePubMedGoogle Scholar
- Steens SC, Admiraal-Behloul F, Bosma GP, Steup-Beekman GM, Olofsen H, Le Cessie S, Huizinga TW, Van Buchem MA: Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum. 2004, 50 (9): 2877-2881. 10.1002/art.20654.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/11/13/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.